Eribulin mesylate injection is an anti-tumor drug, mainly suitable for:
Patients with locally advanced or metastatic breast cancer who have received at least two chemotherapy regimens in the past.
The previous chemotherapy regimen should include an anthracycline and a taxane drug.
Eribulin can directly bind to tubulin to inhibit mitosis, and exerts a therapeutic effect by inhibiting microtubule growth and inhibiting cancer cell growth.
Let us work together to protect precious health